Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) Equity Ratio (2017 - 2025)

KalVista Pharmaceuticals' Equity Ratio history spans 11 years, with the latest figure at 0.38 for Q2 2025.

  • On a quarterly basis, Equity Ratio fell 56.65% to 0.38 in Q2 2025 year-over-year; TTM through Apr 2025 was 0.38, a 56.65% decrease, with the full-year FY2025 number at 0.38, down 56.65% from a year prior.
  • Equity Ratio hit 0.38 in Q2 2025 for KalVista Pharmaceuticals, down from 0.56 in the prior quarter.
  • Over the last five years, Equity Ratio for KALV hit a ceiling of 0.95 in Q2 2021 and a floor of 0.38 in Q2 2025.
  • Historically, Equity Ratio has averaged 0.79 across 4 years, with a median of 0.86 in 2024.
  • Biggest five-year swings in Equity Ratio: increased 4.46% in 2021 and later crashed 56.65% in 2025.
  • Tracing KALV's Equity Ratio over 4 years: stood at 0.95 in 2021, then dropped by 12.76% to 0.82 in 2023, then plummeted by 32.41% to 0.56 in 2024, then crashed by 31.77% to 0.38 in 2025.
  • Business Quant data shows Equity Ratio for KALV at 0.38 in Q2 2025, 0.56 in Q4 2024, and 0.83 in Q4 2024.